Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Korro Bio

Company Type: Therapeutic development

Main focus: Developing RNA editing platforms to treat various diseases

Company stage: Clinical

Diseases: Alpha-1 antitrypsin deficiency, Parkinson’s disease, Amyotrophic lateral sclerosis, and other rare and prevalent diseases

Genome-editing tool: Oligonucleotide promoted editing of RNA (OPERA®)

Funding stage: Post-IPO Equity

Location: Cambridge, Massachusetts, USA

Website: www.korrobio.com

Pipeline: www.korrobio.com/pipeline/

Partners:

Korro Bio is a biopharmaceutical company focused on the development of RNA editing tools to produce novel genetic therapeutics for the treatment of various diseases. The company’s scientific approach involves harnessing naturally occurring mechanisms of RNA editing via an oligonucleotide-based method to edit a single base in the genome. Korro Bio’s pipeline currently includes a trial for KRRO-110, a potential treatment for alpha-1 antitrypsin deficiency (AATD).

Tags

HashtagKorro Bio

Company: Korro Bio
close
Search CRISPR Medicine